5-α-Reductase Inhibition and Prostate Cancer Prevention

Cancer Epidemiology Biomarkers and Prevention

Volumn 3, Issue 2, 1994, Pages 177-182

  Brawley, Otis W ^a   Ford, Leslie G ^a   Perlman, Jeffrey A ^a   Kramer, Barnett S ^a   Thompson, Ian ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

CANCER CELL CULTURE; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; DIHYDROTESTOSTERONE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0028243902     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Boring, C. C., Squires, T. S., and Tong, T. Cancer Statistics, 1993. CA, 43: 7–26.
2. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., and Andriole, G. L. Measurement of prostate-specific antigen as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156–1161, 1991.
3. Thompson, I. M., Ernst, J. J., Gangai, M. P., and Spence, C. R. Adenocarcinoma of the prostate: results of routine urological screening. J. Urol., 132: 690–692, 1984.
4. Chodak, G. W., Thompson, I. M., and Gerber, G. S. Results from two prostate cancer screening programs. J. Urol., 145: 251–256, 1991.
5. Hinman, F. Screening for prostatic carcinoma. J. Urol., 145: 125–129, 1991.
6. Kramer, B. S., Brown, M. L., Prorok, P. C. Potosky, A. L., and Gohagan, J. K. Prostate cancer screening: what we know and what we need to know. Ann. Intern. Med., 7/9: 914–923, 1993.
7. Hovenian, M. S., and Deming, C. L. The heterologous growth of cancer of the human prostate. Surg. Gynecol. Obstet., 86: 29–35, 1948.
8. Ghanadian, R., Puah, K. M., and O’Donohue, E. P. M. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 39: 696–699, 1979.
9. Wynder, E. R., Mabuchi, K. and Whitmore, W. Epidemiology of cancer of the prostate. Cancer (Phila.), 28: 344–360, 1971.
10. Ross, R. K., Bernstein, L., and Judd, H. Serum testosterone levels in young black and white men. J. Natl. Cancer Inst., 76: 45–48, 1976.
11. Sakr, W. A., Haas, G. P., and Grignon, L. K. High grade prostatic intra- epithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. (Abstract) Mod. Pathol., 6: 68, 1993.
12. Carter, B. S., Steinberg, G. D., Beaty, T. H., and Walsh, P. C. Evidence for Mendelian inheritance in the pathogenesis of prostate cancer. (Abstract) J. Urol., 745: 213A, 1991.
13. Babain, R. J., Spitz, M. R., Currier, R. D., Fueger, J. J., and Newell, G. R. Familial patterns of prostate cancer: a case-control analysis. (Abstract) J. Urol., 745: 213A, 1991.
14. Deetch, D. W., and Catalona, W. J. Familial aspects of prostate cancer: a case control review. (Abstract) j. Urol., 745: 250A, 1991.
15. Miller, B. A., Ries, L. A. G., Hankey, B. F., Kosary, C. L., and Edwards, B. K. (eds.). Cancer Statistics Review: 1973-1989. NIH Publication No. 92-2789, Bethesda, MD: National Cancer Institute, 1992.
16. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., and Pike, M. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887–889, 1992.
17. Stemmermann, G. N., Nomura, A. M. Y., Chyou, P-H., and Yatani, R. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol., Biomarkers & Prev., 7: 189–193, 1992.
18. Yatani, R., Chigusa, I., Akazaki, K., Stemmermann, G. N., Welsh, R. A., and Correa, P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer, 29: 611–616, 1982.
19. Breslow, N., Chan, C. W., Dhom, G., Drury, R. A. B., Granks, L. M., Gellei, B., Lee, Y. S., Lundberg, S., Sparke, B., Sternby, N. H., and Tulinius, H. Latent carcinoma of the prostate at autopsy in seven areas. Int. J. Cancer, 20: 680–688, 1977.
20. Adlercreutz, H. Western diet and western diseases: some hormonal and biochemical mechanisms and associations. Scand. J. Clin. Lab. Invest., 50(Suppl.): 3–23, 1990.
21. Hamalainen, E., Adlercreutz, H., Puska, P., and Pietinen, P. Diet and serum hormones in healthy men. J. Steroid Biochem., 20: 459–464, 1984.
22. Coffey, D. S. Physiological control of prostatic growth. In: Prostate Cancer, an Overview, pp 4–23. UICC Workshop on Prostatic Cancer, 1978. Technical Report Series, Vol. 48, Geneva: International Union Against Cancer, 1979.
23. Giovannucci, E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. C., and Willett, W. C. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst., 85: 1571–1579, 1993.
24. Lookingbill, D. P., Demers, L. M., Wang, C., Leung, A., Rittmaster, R. S., and Santen, R. J. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab., 72: 122–1248, 1991.
25. Grino, P. B., Griffin, J. E., and Wilson, J. D. Testosterone at high concentration interacts with the human androgen receptor similar to dihydrotestosterone. Endocrinology, 726: 1165–1172, 1988.
26. Kyprianou, N., and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 722: 552–562, 1988.
27. Bruchovsky, N., Rennie, P. S., Batzold, F. H., Goldenberg, S. L., Fletcher, T., and McLoughlin, M. G. Kinetic parameters of 5-alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J. Clin. Endocrinol. Metab., 67: 806–816, 1988.
28. Anderson, S., Berman, D. M., Jenkins, E. P., and Russell, D. W. Deletion of steroid 5-alpha-reductase-2 gene in male pseudohermaproditism. Nature (Lond.), 354: 159–161, 1991.
29. Anderson, K. M., and Liao, S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature (Lond.), 279: 277–279, 1968.
30. Grino, P. B., Griffin, J. E., and Wilson, J. D. Testosterone at high concentration interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology, 726: 1165–1171, 1989.
31. Petersen, R. E., Imperato-McGinley, J., Gautier, T., and Sturla, E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am. J. Med., 62: 170–191, 1977.
32. Imperato-McGinley, J. L., Cai, L., Orlic, S. D., Markisz, J. A., and Vaughan, E. D. Long-term treatment of benign prostatic hyperplasia with the 5-alpha-reductase inhibitor finasteride (MK-906) (Abstract) J. Urol., 745: 265A, 1991.
33. Rittmaster, R. S., Lemay, A., Zwicker, H., Capizzi, T. P., Winch, S., Moore, E., and Gormley, G. J. Effect of finasteride, a 5-alpha-reductase inhibitor, on serum gonadotropins in normal men. J. Clin. Endocrinol. Metab., 75(2): 484–488, 1992.
34. Cabot, A. T. The question of castration for enlarged prostate. Ann. Surg., 24: 265–309, 1896.
35. Presti, J. C., Fair, W. R., Andriole, G., Sogani, P. C., Seidmon, E. J., Ferguson, D., Ng, J., and Gormley, G. J. J Urol, 748(4): 1201–1204, 1992.
36. Imperato-McGinley, J. L., Cai, L., Orlic, S. D., Markisz, J. A., and Vaughan, E. D. Long-term treatment of benign prostatic hyperplasia with the 5-alpha-reductase inhibitor finasteride (MK-906) (Abstract) J. Urol. 745: 265A, 1991.
37. Huggins, C., and Hodges, C. V. Studies on prostate cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 7: 293-297, 1941.
38. Santen, R. J., and Warner, B. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate. Urology; 25(Suppl 2): 53–57, 1985.
39. Geller, J., Albert, J., and Vik, A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin. Oncol., 75: 53, 1988.
40. Buttyan, R., and Olsson, C. A. Androgen receptor assays in advanced prostatic cancer. Urol. Clin. North Am. 77: 311–317, 1984.
41. Tohjoh, S. A study on usefulness of the crude nuclear DHT measurement in prostatic cancer patients. Nippon Hinyokika Gakkai Zasshi, 80: 1327–1335, 1989.
42. Chodak, G. W., Kranc, D. M., and Puy, L. A. Nuclear localization of androgen receptor in heterogeneous sample of normal, hyperplastic and neoplastic human prostate J. Urol., 747: 798–803, 1992.
43. Meyer, J. S., Sufrin, G., and Martin, S. A. Proliferative activity of benign human prostate, prostatic adenocarcinomas and seminal vesicle evaluated by thymidine labeling. J. Urol., 728: 1353–1356, 1982.
44. Carter, H. B., and Isaacs, J. T. Experimental and theoretical basis for hormonal treatment of prostatic cancer. Semin. Urol., 6: 262–266, 1988.
45. Noble, R. L. The development of prostatic adenocarcinoma in NB rats following prolonged sex hormone administration. Cancer Res., 79: 1125–1139, 1959.
46. Kadoham, N., Karr, J. P., Murphy, G. P., and Sandberg, A. A. Selective inhibition of prostatic tumor 5 alpha-reductase by a 4-methyl-4-aza-steroid. Cancer Res., 44: 4947–4950, 1984.
47. Petrow, V., Padilla, G. M., Mukherji, S. and Marts, S. A. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J. Pharm. Pharmacol., 36: 352–353, 1984.
48. Bologna, M., Muzi, P., Biordi, L., and Pestuccia, C. Vicentini. Antiandrogens and 5-alpha-reductase inhibition of the proliferation rate in PC3 and DU 145 human prostatic cancer cell lines. Curr. Ther. Res., 5: 799–813, 1992.
49. Damber, J. E., Bergh, A., Daehlin, L., Petrov, V., and Landstrom, M. Effect of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma. Prostate, 20: 187–190, 1992.
50. Lamb, J. C., English, H., Levandoski, P. L., Rhodes, G. R., Johnson, R. K., and Isaacs, J. R. Prostatic involution in rats induced by a novel 5-alpha- reductase inhibitor, SK, and F 105657: role for testosterone in the androgenic response. Endocrinology, 730: 685–694, 1992.
51. Brooks, J. R., Berman, C., and Nguyen, H. Effect of castration, DES, flutamide, and the 5-alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate, 78: 215–227, 1991.
52. Bruun, E., Grandsen, H., Nielsen, K., Rasmussen, L. B., Vinnergaard, T., and Grimodt-Miller, C. Dihydrotestosterone measured in core biopsies from prostatic tissues. Am. J. Clin. Oncol., 77(Suppl 2): S27–S29, 1988.
53. Habib, G. K., Bissas, A., Neill, W. A., Busuttil, A., and Chisholm, G. D. Flow cytometric analysis of cellular DNA in human prostate cancer: relationship to 5-alpha-reductase activity of the tissue. Urol. Res., 77; 239–243, 1989.
54. Presti, J. C., Fair, W. R., Andriole, G., Sogani, P. C., Seidman, Ferguson D., Ng, J., and Gormley, G. Multicenter, randomized, double-blind, placebo- controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer, J. Urol., 148: 1201–1204, 1992.
55. George, F. W., Johnson, L., and Wilson, J. D. The effect of a 5-alpha- reductase inhibitor on androgen physiology in the immature male rat. Endocrinology, 723: 2434–2438, 1989.
56. Imperato-McGinley, J., Shackleton, C., Orlic, S., and Stoner, E. C,9 and C2i 5-beta/5-alpha metabolite ratios in subjects treated with the 5-alpha- reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5-alpha-reductase deficiency. J. Clin. Endocrinol. Metab., 70: 777–782, 1990.
57. Gormley, G. J., Stoner, E., Rittmaster, R. S., Gregg, H., Thompson, D. L., Lasseter, K. C., Vlassess, P. H., and Stein, E. A. Effects of finasteride (MK-906), a 5-alpha-reductase inhibitor on circulating androgens in male volunteers. J. Clin. Endocrinol. Metab., 70: 1136–1141, 1990.
58. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. O., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med., 327: 1185–1191, 1992.
59. Gormley, G. J. Role of 5-alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol. Clin. North Am., 78: 93–98, 1991.
60. Cook, T., Stoner, E., Shapiro, D., and the Finasteride Study Group. Efficacy is maintained with long-term use of finasteride, with no increase in adverse experieces. (Abstract) J. Urol. 749: 431 A, 1993.
61. Guess, H. A., Heyse, J. F., and Gormely, G. J. The effect of finasteride on prostate-sepcific antigen in men with benign prostatic hyperplasia. Prostate, 22: 31–37, 1993.
62. Bostwick, D. The pathology of early prostate cancer. CA Cancer J. Clin., 39: 376–381, 1989.